S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer

Colorectal Cancer Clinical Trial

Official title:

A Randomized Phase II Study of Comparing S-1/Leucovorin With sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01193452
• Other study ID #: SL-eCRC
• Status: Recruiting
• Phase: Phase 2
• First received: August 31, 2010
• Last updated: September 1, 2010
• Start date: August 2010
• Est. completion date: February 2012

Study information

• Verified date: August 2010
• Source: Fudan University
• Contact: Jin Li, MD,PhD
• Phone: 64175590
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

This phase II trial on the assumption that S-1 combined with Leucovorin may have better efficacy and safety than simplified 5-FU/LV infusion therapy in elderly patients with advanced colorectal cancer.

Description:

This is a randomized phase Ⅱ study, in which S-1 is used in combination with leucovorin in elderly patients with advanced colorectal cancer as first-line treatment,comparing with sLV5FU2 therapy. The aim of this study is to determine the efficacy and safety of S-1/LV in elderly patients in the first-line setting. The other secondary endpoints are progression free survival,overall survival, and quality of life are also evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: February 2012
• Est. primary completion date: February 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Signed written informed consent

• Oral medication is acceptable

• Histologically confirmed colorectal carcinoma

• Male or female = 65 years of age

• No prior chemotherapy,radiotherapy,target therapy and immunotherapy, except adjuvant chemotherapy with an interval of = 180 days)

• Presence of at least one target lesion measurable by CT scan or MRI,within 15 days prior to trial

• The lab values within 2 weeks prior to trial should meet:

PLT =7.5*10^4/mm3 ANC=2000/mm3 HB=100g/L Total bilirubin < upper limit of normal level ALT/AST/ALP < 2.5 x UNL (<5 x UNL for patients with liver or bone metastasis) Serum creatinine < UNL

• Performance status (ECOG) 0~1

• Life expectation longer than 90 days

Exclusion Criteria:

• Allergy to S-1,fluorouracil or leucovorin

• Any investigational agent(s) within 4 weeks prior to entry

• Previous or currently exposure to certain drugs which are proved to have influence on blood drug concentration

• Active infection

• Severe organ failures or diseases, including: intestinal obstruction, pulmonary fibrosis, uncontrolled diabetes mellitus,clinically relevant coronary disease, cardiovascular disorder or myocardial infarction,renal or liver failure, severe psychiatric illness,cerebral vascular disease and sever GI ulcer which need blood infusion.

• Uncontrolled hydrothorax,ascites and hydropericardium

• Multiple bone metastatic lesions

• Brain metastases

• Chronic diarrhea or digestive disfunction

• Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)

• Strong willingness to receive surgery or highly potential to have intestinal obstruction which may need surgery intervention

• Other conditions that primary investigate or investigator consider to be unsuitable for the trial

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• S-1, Leucovorin
S-1 : The initial dosage of S-1 is determined by the body surface area: Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day Leucovorin: 25mg twice per day po. The treatment is given for one week,and no chemotherapy is given for the following one week.
• leucovorin, 5-fluorouracil
leucovorin: 400mg/m2 intravenous infusion d1; 5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours repeat every 2 weeks

Locations

Country	Name	City	State
China	Jin Li`	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	response rate		six weeks	No
Secondary	progression free survival		six weeks	No
Secondary	disease control rate		six weeks	No
Secondary	time to treatment failure		six weeks	No
Secondary	overall survival		three months	No
Secondary	quality of life		six weeks	Yes
Secondary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability		six weeks	Yes